Dunedin cancer diagnostic company Pacific Edge has been
granted patent protection by the United States Patent Office
for ''prognosis prediction for melanoma'' - a crucial move
further broadening its product development into a variety of
Pacific Edge's mainstay line is its diagnostic Cx-bladder
product, but the US patent covers the technology being used
to develop a melanoma prognostic test, to distinguish
aggressive and life-threatening melanomas from those not as
Following a trading halt, Pacific Edge shares resumed, up
almost 5% at 86c.
Melanoma prognosis patents are already held in China and New
Zealand, but under the US patent, Pacific Edge has partnered
with the Ludwig Institute of Cancer Research, the world's
largest non-profit cancer research organisation, to develop
the technology, Pacific Edge chief executive David Darling
''This successful partnership has enabled Pacific Edge to
develop the prototype product for detecting aggressiveness in
stage 3 melanomas,'' he said.
The test applied a gene signature to melanoma tissue samples
to detect its aggressiveness, allowing doctors to prescribe
the correct level of treatment.
''It is the aggressive tumours that will kill you.
Specifically, the test in development identifies
aggressiveness in stage 3 melanomas,'' Mr Darling said.
Already being heavily marketed in the US, Cx-bladder is a
quick, cost-effective, non-invasive and highly accurate test
to detect bladder cancers.
The company's development programme is seeking to validate
Cx-bladdertriage, a new product to segregate those with blood
in their urine, but not because of bladder cancer, and
Cx-bladderpredict, which determines bladder cancer severity,
segregating superficial tumours from invasive tumours.
Pacific Edge's portfolio of intellectual property, in which
it invests between $450,000 and $500,000 a year, continues to
grow and includes patents for a gastric cancer test, plus
melanoma and bladder cancers.